You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience

Article info

Article menu
Download PDFPDF
ePoster
EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience

Authors

Citation

Akaev I, Chau C, Uherek M, et al
EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience
International Journal of Gynecologic Cancer 2019;29:A429.

Publication history

  • First published November 1, 2019.
Online issue publication 
March 03, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.